Patients with extramedullary plasma cell tumors (ExPCTs)
Patient name . | PC, %*medullary at diagnosis of MM . | PC, %*medullary when ExMM diagnosed . | ExPCT location . | PC, %†extramedullary . | Time‡ . | Status§ . |
|---|---|---|---|---|---|---|
| Simultaneously diagnosed medullary and extramedullary disease | ||||||
| ExPCT-1C | 44 | 44 | Orbit | 100 | 4 | Dead |
| ExPCT-4 | 5 | 5 | Pleura | 4 | 12 | Dead |
| ExPCT-7C | 7 | 7 | Lymph node | 100 M | 63 | Dead |
| ExPCT-8 | 42 | 42 | Tumor pelvis | 6 | 48 | PR |
| ExPCT-10 | 8 | 8 | Thorax, upper limb | NA | 42 | PR |
| Medullary phase followed by extramedullary phase | ||||||
| ExPCT-2C | 10 | 19 | Hypophysis | 12 | 17 | Dead |
| ExPCT-5C | 25 | 35 | Soft tissue | 13 | 71 | Dead |
| ExPCT-12 | 40 | 36 | Intraspinal-lumbosacralcoluma | NA | 27 | Dead |
| ExPCT-13C | 32 | 2∥ | Intraspinal, cervico-thoracal | 100 M | 7 | Dead |
| Extramedullary phase with less than 5%†medullary PC | ||||||
| ExPCT-3C | < 5 | 1.3∥ | Ascites/peritoneum (lower limb, gastrointestinal tract, skin)¶ | 12 M | 80 | Dead |
| ExPCT-6 | 0.5 | 0.5 | Pleura | 77 | 9 | Dead |
| ExPCT-10 | 1.2 | < 5 | (Mammae and skin)¶ | NA | 71 | Dead |
| ExPCT-12 | 1.1 | 0.5 | Pleura (thorax wall)¶ | 0.6 | 12 | CR |
Patient name . | PC, %*medullary at diagnosis of MM . | PC, %*medullary when ExMM diagnosed . | ExPCT location . | PC, %†extramedullary . | Time‡ . | Status§ . |
|---|---|---|---|---|---|---|
| Simultaneously diagnosed medullary and extramedullary disease | ||||||
| ExPCT-1C | 44 | 44 | Orbit | 100 | 4 | Dead |
| ExPCT-4 | 5 | 5 | Pleura | 4 | 12 | Dead |
| ExPCT-7C | 7 | 7 | Lymph node | 100 M | 63 | Dead |
| ExPCT-8 | 42 | 42 | Tumor pelvis | 6 | 48 | PR |
| ExPCT-10 | 8 | 8 | Thorax, upper limb | NA | 42 | PR |
| Medullary phase followed by extramedullary phase | ||||||
| ExPCT-2C | 10 | 19 | Hypophysis | 12 | 17 | Dead |
| ExPCT-5C | 25 | 35 | Soft tissue | 13 | 71 | Dead |
| ExPCT-12 | 40 | 36 | Intraspinal-lumbosacralcoluma | NA | 27 | Dead |
| ExPCT-13C | 32 | 2∥ | Intraspinal, cervico-thoracal | 100 M | 7 | Dead |
| Extramedullary phase with less than 5%†medullary PC | ||||||
| ExPCT-3C | < 5 | 1.3∥ | Ascites/peritoneum (lower limb, gastrointestinal tract, skin)¶ | 12 M | 80 | Dead |
| ExPCT-6 | 0.5 | 0.5 | Pleura | 77 | 9 | Dead |
| ExPCT-10 | 1.2 | < 5 | (Mammae and skin)¶ | NA | 71 | Dead |
| ExPCT-12 | 1.1 | 0.5 | Pleura (thorax wall)¶ | 0.6 | 12 | CR |
C (in ExPCT-1C and similar constructions) indicates clonal lgH; M, RAS mutation in extramedullary but not intramedullary tumor cells; PR, partial remission; NA, not available; and CR, complete remission.
PC% determined morphologically.
For determination of PC% in extramedullary locations and when < 5% PCs were observed morphologically, aberrant PC percentages were determined by flow cytometry as described in “Patients, materials, and methods.”
Observation time in months after diagnosis.
Status at the observation time after diagnosis.
These patients were under treatment, which may result in low medullary tumor burden.
Multiple locations, the locations in parentheses were not available for analysis.